4 results
6-K
EX-1.1
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
by the Company, which would have a Material Adverse Effect.
(ii) Cybersecurity. (i)(x) There has been no security breach or other compromise of or relating
6-K
EX-10.1
ENLV
Enlivex Therapeutics Ltd
30 Dec 22
Report of Foreign Private Issuer
4:02pm
not been described as required.
(qq) Cybersecurity. The Company and its subsidiaries’ information technology assets and equipment, computers, systems
- Prev
- 1
- Next